Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

A 35-year-old is considering Breezula, Pyrilutamide, or topical finasteride/dutasteride to protect against hair loss while on testosterone replacement therapy (TRT). They currently use finasteride, oral minoxidil, and dutasteride but experienced increased hair shedding with TRT.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

The user experienced hair improvement using a topical finasteride, minoxidil, and tretinoin combo, along with supplements like zinc, copper, magnesium, vitamin D3, K2, iodine, and boron. They believe these changes are due to addressing mineral deficiencies and possibly thyroid issues, despite skepticism from others.

The conversation is about a homemade hair loss treatment serum containing Procyanidin B2, Aloe Vera Gel, Coconut Oil, Castor Oil, and Rosemary Essential Oil. The main concern is finding an affordable source of Procyanidin B2 and ensuring its stability in the serum at room temperature.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

PRP may help with thinning hair but not in completely bald areas. Some users report no noticeable difference after treatment.

High prolactin levels may contribute to hair loss, and some users suggest supplements like mucuna pruriens, vitamin B6, vitamin E, L-Tyrosine, L-Theanine, DIM, and Zinc to lower prolactin. Lifestyle changes to increase dopamine, such as reducing screen time and stress, are also recommended.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

The conversation discusses using adjunct therapies like scalp massage and Botox to enhance the effects of DHT inhibitors for hair loss. It also mentions using GHK-cu, finasteride, keto shampoo, and a natural topical DHT-reducing serum for hair regrowth and reduced shedding.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

A user experienced libido issues after using finasteride for five months, with elevated prolactin and estradiol levels. The discussion includes differing opinions on whether these symptoms are due to hormonal imbalances or post-finasteride syndrome.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

The user experienced positive scalp results with Dutasteride but noticed beard thinning, prompting a switch back to Finasteride. They plan to monitor the situation and may consider combining treatments in the future.

Dutasteride is safer than finasteride for long-term use, with fewer sexual side effects. Users experience better hair regrowth and fewer side effects with dutasteride.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.